Skip to main content
. 2020 Apr 28;6(1):e001161. doi: 10.1136/rmdopen-2019-001161

Figure 1.

Figure 1

(A) Mean number of AAU flares pre- and post-baseline. (B) Proportion of patients experiencing AAU flares pre- and post-baseline. Safety Set (N=89). Four patients had an AAU flare in the 12 months prior to baseline but not during the 48-week pretreatment period. AAU, acute anterior uveitis; CZP, certolizumab pegol; Q2W, every 2 weeks.